Subscribe / Unsubscribe Enewsletters | Login | Register

Pencil Banner

IBM’s Watson to use genomic data to defeat drug-resistant cancers

Lucas Mearian | Nov. 11, 2016
The five-year, $50 million project will study thousands of drug-resistant tumors

Watson for Genomics will sift through anonymized patient data that will be made available to the scientific community to catalyze research worldwide, and uncover hidden patterns that could help scientists better understand the molecular underpinnings behind cancer treatment resistance.

"The Broad Institute is leading the industry in areas of cancer biology, genomics and computational biology, and we are proud to bring Watson's data prowess to help researchers learn more about one of most important medical challenges that too often stands in the way of effective cancer treatment," John Kelly III, IBM Research's senior vice president of Cognitive Solutions, said in a statement. "Our hope is that this effort, if successful, could eventually lead to significant breakthroughs. Someday, patients who would not otherwise have options in their battle against cancer may have reason for hope."


Previous Page  1  2 

Sign up for CIO Asia eNewsletters.